ABCL vs SYRE
AbCellera Biologics Inc. vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
64
Buy
VS
SYRE
Spyre Therapeutics, Inc.
68
Buy
| Metric | ABCL | SYRE |
|---|
| AI Score |
64
|
68
|
| Price |
$10.35
|
$104.13
|
| P/E Ratio |
-18.07×
|
-52.69×
|
| ROE |
-15.1%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
0.0%
|
| Debt / Equity |
0.15×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
53.3
|
| Beta |
1.191
|
3.026
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ABCL versus SYRE.
SYRE leads by 4 points.
SYRE scores 68/100 (Buy) versus ABCL at 64/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical